as hydrate: InChI=1S/4C23H15N3O.3H2O/c4*24-15-17-8-4-5-11-20(17)21-14-18(22-12-6-7-13-25-22)16-26(23(21)27)19-9-2-1-3-10-19;;;/h4*1-14,16H;3*1H2
Key:PDWMJDKMSASBNE-UHFFFAOYSA-N
NY (what is this?)(verify)
Perampanel, sold under the brand name Fycompa, is an anti-epileptic medication developed by Eisai Co. that is used in addition to other drugs to treat partial seizures and generalized tonic-clonic seizures for people older than twelve years.[8] It was first approved in 2012, and as of 2016[update], its optimal role in the treatment of epilepsy relative to other drugs was not clear.[10] It was the first antiepileptic drug in the class of selective non-competitive antagonist of AMPA receptors.[11]
The drug label has a black box warning that the drug may cause serious psychiatric and behavioral changes; it may cause homicidal or suicidal thoughts.[8] Other side effects have included dizziness, somnolence, vertigo, aggression, anger, loss of coordination, blurred vision, irritability, and slurred speech.[8] Perampanel reduced the effectiveness of levonorgestrel oral contraceptives by about 40%.[8] Women who may get pregnant should not take it as studies in animals show it may harm a fetus.[12] Perampanel is liable to be abused; very high doses produced euphoria responses similar to ketamine.[8] It is designated as a Schedule III controlled substance by the Drug Enforcement Administration.[8]
As of August 2016 perampanel had been studied and development discontinued in migraine, multiple sclerosis, neuropathic pain, and Parkinson's disease.[13]
^"FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 October 2023.
^"AusPAR: Perampanel hemisesquihydrate". Therapeutic Goods Administration (TGA). 10 May 2021. Retrieved 12 June 2021.
^"TGA eBS - Product and Consumer Medicine Information Licence".
^"Fycompa". NPS MedicineWise. 15 July 2021. Retrieved 19 February 2022.
^"Prescription medicines: registration of new chemical entities in Australia, 2014". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 10 April 2023.
^Anvisa (31 March 2023). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 4 April 2023). Archived from the original on 3 August 2023. Retrieved 16 August 2023.
^"Product monograph brand safety updates". Health Canada. February 2024. Retrieved 24 March 2024.
Perampanel, sold under the brand name Fycompa, is an anti-epileptic medication developed by Eisai Co. that is used in addition to other drugs to treat...
receptors The noncompetitive AMPA receptor antagonists talampanel and perampanel have been demonstrated to have activity in the treatment of adults with...
MCT ketogenic diet. Decanoic acid and the AMPA receptor antagonist drug perampanel act at separate sites on the AMPA receptor, and so it is possible that...
an anxiolytic since 1975 and as an anticonvulsant since 1984 Fycompa (perampanel) – an anti-epileptic medication which can cause serious psychiatric and...
Name: Felbamate Levetiracetam Zonisamide Topiramate Valproate Lamotrigine Perampanel Valproate, a relatively old drug, is often considered the first-line treatment...
combination with other drugs, such as opioids or alcohol. Ethosuximide and perampanel can also produce euphoria at therapeutic doses. μ-Opioid receptor agonists...
oxcarbazepine, phenobarbital, phenytoin, primidone, and rufinamide. The drugs perampanel and topiramate can be enzyme-inducing at higher doses. Conversely, hormonal...
Global Information
(what is this?) (verify)